Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California. more
Time Frame | RNXT | Sector | S&P500 |
---|---|---|---|
1-Week Return | 18.49% | -1.8% | -0.77% |
1-Month Return | 21.55% | -3.48% | 0.71% |
3-Month Return | 34.21% | -7.2% | 8.81% |
6-Month Return | 34.29% | -1.54% | 12.32% |
1-Year Return | 120.31% | 8.39% | 30.57% |
3-Year Return | -75.65% | 6.07% | 29.21% |
5-Year Return | -80.58% | 44.07% | 91.95% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | - | - | 9.00K | 6.00K | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":66.67,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Profit | - | - | (9.00K) | (6.00K) | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-900000,"profit":false},{"date":"2022-12-31","value":-600000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Gross Margin | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 3.90M | 3.20M | 5.67M | 9.95M | 11.40M | [{"date":"2019-12-31","value":34.19,"profit":true},{"date":"2020-12-31","value":28.12,"profit":true},{"date":"2021-12-31","value":49.76,"profit":true},{"date":"2022-12-31","value":87.31,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (3.90M) | (3.20M) | (5.67M) | (9.95M) | (11.40M) | [{"date":"2019-12-31","value":-389600000,"profit":false},{"date":"2020-12-31","value":-320400000,"profit":false},{"date":"2021-12-31","value":-567100000,"profit":false},{"date":"2022-12-31","value":-995000000,"profit":false},{"date":"2023-12-31","value":-1139600000,"profit":false}] |
Total Non-Operating Income/Expense | 120.00K | (1.18M) | (1.49M) | 118.00K | 1.27M | [{"date":"2019-12-31","value":9.41,"profit":true},{"date":"2020-12-31","value":-92.63,"profit":false},{"date":"2021-12-31","value":-116.63,"profit":false},{"date":"2022-12-31","value":9.25,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (3.84M) | (3.80M) | (6.32M) | (9.89M) | (10.23M) | [{"date":"2019-12-31","value":-383900000,"profit":false},{"date":"2020-12-31","value":-379800000,"profit":false},{"date":"2021-12-31","value":-632400000,"profit":false},{"date":"2022-12-31","value":-988900000,"profit":false},{"date":"2023-12-31","value":-1023200000,"profit":false}] |
Income Taxes | (63.00K) | 587.00K | 772.00K | (118.00K) | (6.00) | [{"date":"2019-12-31","value":-8.16,"profit":false},{"date":"2020-12-31","value":76.04,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-15.28,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (3.78M) | (4.38M) | (7.10M) | (9.77M) | (10.23M) | [{"date":"2019-12-31","value":-377600000,"profit":false},{"date":"2020-12-31","value":-438500000,"profit":false},{"date":"2021-12-31","value":-709600000,"profit":false},{"date":"2022-12-31","value":-977100000,"profit":false},{"date":"2023-12-31","value":-1023199400,"profit":false}] |
Income From Continuous Operations | (3.84M) | (3.80M) | (6.32M) | (9.89M) | (9.16M) | [{"date":"2019-12-31","value":-383900000,"profit":false},{"date":"2020-12-31","value":-379800000,"profit":false},{"date":"2021-12-31","value":-632400000,"profit":false},{"date":"2022-12-31","value":-988900000,"profit":false},{"date":"2023-12-31","value":-916100000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (3.78M) | (4.38M) | (7.10M) | (9.77M) | (10.23M) | [{"date":"2019-12-31","value":-377600000,"profit":false},{"date":"2020-12-31","value":-438500000,"profit":false},{"date":"2021-12-31","value":-709600000,"profit":false},{"date":"2022-12-31","value":-977100000,"profit":false},{"date":"2023-12-31","value":-1023200000,"profit":false}] |
EPS (Diluted) | (0.48) | (0.86) | (1.44) | (1.09) | (1.11) | [{"date":"2019-12-31","value":-47.88,"profit":false},{"date":"2020-12-31","value":-86.05,"profit":false},{"date":"2021-12-31","value":-144.33,"profit":false},{"date":"2022-12-31","value":-109,"profit":false},{"date":"2023-12-31","value":-111,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
RNXT | |
---|---|
Cash Ratio | 5.40 |
Current Ratio | 5.66 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
RNXT | |
---|---|
ROA (LTM) | -70.08% |
ROE (LTM) | -155.12% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
RNXT | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.30 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.70 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
RNXT | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 4.65 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
RenovoRx Inc (RNXT) share price today is $1.41
Yes, Indians can buy shares of RenovoRx Inc (RNXT) on Vested. To buy RenovoRx Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in RNXT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of RenovoRx Inc (RNXT) via the Vested app. You can start investing in RenovoRx Inc (RNXT) with a minimum investment of $1.
You can invest in shares of RenovoRx Inc (RNXT) via Vested in three simple steps:
The 52-week high price of RenovoRx Inc (RNXT) is $2.35. The 52-week low price of RenovoRx Inc (RNXT) is $0.68.
The price-to-earnings (P/E) ratio of RenovoRx Inc (RNXT) is
The price-to-book (P/B) ratio of RenovoRx Inc (RNXT) is 4.65
The dividend yield of RenovoRx Inc (RNXT) is 0.00%
The market capitalization of RenovoRx Inc (RNXT) is $34.32M
The stock symbol (or ticker) of RenovoRx Inc is RNXT